Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer | Zendy

Akito Hata | Zendy; Nobuyuki Katakami | Zendy; Shigeki Nanjo | Zendy; Chiyuki Okuda | Zendy; Reiko Kaji | Zendy; Katsuhiro Masago | Zendy; Shiro Fujita | Zendy; Hiroshi Yoshida | Zendy; Kota Zama | Zendy; Yukihiro Imai | Zendy; Yukio Hirata | Zendy

Open Access

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer

Author(s) -

Akito Hata,

Nobuyuki Katakami,

Shigeki Nanjo,

Chiyuki Okuda,

Reiko Kaji,

Katsuhiro Masago,

Shiro Fujita,

Hiroshi Yoshida,

Kota Zama,

Yukihiro Imai,

Yukio Hirata

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.22837

Subject(s) - medicine , epidermal growth factor receptor , lung cancer , immunohistochemistry , oncology , cancer , pathology , cancer research

Current clinical trials have suggested poorer efficacies of anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) immunotherapies for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor ( EGFR ) mutations, implying lower PD-L1 expression in EGFR -mutant NSCLC than in EGFR -wild type.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research